Globally, approximately 32% of people with type 2 diabetes are affected by cardiovascular diseases [21]
GLP-1R mRNA and GLP-1 immunoreactivity was detected in the VTA and NAc, as well as other reward associated areas including lateral hypothalamus, lateral habenula, hippocampus, and substantia nigra (Merchenthaler et al., 1999)
Until advanced transdermal delivery systems complete rigorous clinical trials, patches remain an unproven alternative to established GLP-1 injection therapies
Dose adjustments may help if side effects are problematic, and your provider can assess whether additional supportsuch as anti-nausea medication or mental health counselingmight be beneficial
The patience required during dose escalation is actually one of the most valuable aspects of the protocol
Combination therapies Tirzepatide: Combines GLP-1 and GIP receptor agonism for dual-action benefits